Jeffrey R. Willis

2.0k total citations · 1 hit paper
47 papers, 1.2k citations indexed

About

Jeffrey R. Willis is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Jeffrey R. Willis has authored 47 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Ophthalmology, 27 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Epidemiology. Recurrent topics in Jeffrey R. Willis's work include Retinal Diseases and Treatments (33 papers), Retinal Imaging and Analysis (26 papers) and Glaucoma and retinal disorders (10 papers). Jeffrey R. Willis is often cited by papers focused on Retinal Diseases and Treatments (33 papers), Retinal Imaging and Analysis (26 papers) and Glaucoma and retinal disorders (10 papers). Jeffrey R. Willis collaborates with scholars based in United States, United Kingdom and Switzerland. Jeffrey R. Willis's co-authors include Zdenka Hašková, Pradeep Y. Ramulu, Susan Vitale, Marco Prunotto, Andreas Maunz, Fethallah Benmansour, Filippo Arcadu, Ronald A. Cantrell, Lawrence S. Morse and Suzanne W. van Landingham and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes and Ophthalmology.

In The Last Decade

Jeffrey R. Willis

40 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deep learning algorithm predicts diabetic retinopathy progression in individual patients

2019 188 citations Filippo Arcadu, Fethallah Benmansour et al. npj Digital Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey R. Willis United States	18	684	632	200	88	79	47	1.2k
E Shyong Tai Singapore	17	412 0.6×	380 0.6×	224 1.1×	26 0.3×	102 1.3×	33	1.1k
Preeti Gupta Singapore	23	1.6k 2.3×	1.2k 1.9×	383 1.9×	19 0.2×	88 1.1×	86	2.1k
Stuart Keel Australia	23	1.6k 2.3×	1.5k 2.3×	409 2.0×	50 0.6×	79 1.0×	86	2.3k
J J Wang Australia	21	990 1.4×	942 1.5×	179 0.9×	28 0.3×	77 1.0×	28	1.4k
Gabriella Tikellis Australia	26	1.0k 1.5×	911 1.4×	136 0.7×	150 1.7×	240 3.0×	65	1.9k
Sahil Thakur Singapore	18	678 1.0×	580 0.9×	189 0.9×	16 0.2×	72 0.9×	91	1.1k
Wanjiku Mathenge United Kingdom	25	1.4k 2.1×	1.1k 1.7×	741 3.7×	328 3.7×	93 1.2×	58	2.1k
Risa M. Wolf United States	20	213 0.3×	231 0.4×	243 1.2×	40 0.5×	113 1.4×	76	1.0k
Adir Sommer Israel	13	810 1.2×	609 1.0×	112 0.6×	57 0.6×	125 1.6×	31	1.3k
Jonathon Q. Ng Australia	22	805 1.2×	397 0.6×	464 2.3×	37 0.4×	69 0.9×	58	1.4k

Countries citing papers authored by Jeffrey R. Willis

Since Specialization

Citations

This map shows the geographic impact of Jeffrey R. Willis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey R. Willis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey R. Willis more than expected).

Fields of papers citing papers by Jeffrey R. Willis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey R. Willis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey R. Willis. The network helps show where Jeffrey R. Willis may publish in the future.

Co-authorship network of co-authors of Jeffrey R. Willis

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey R. Willis. A scholar is included among the top collaborators of Jeffrey R. Willis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey R. Willis. Jeffrey R. Willis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eichenbaum, David, Arshad M. Khanani, Dante J. Pieramici, et al.. (2025). Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. American Journal of Ophthalmology. 275. 14–26.

Danzig, Carl J., Christiana Dinah, Faruque Ghanchi, et al.. (2025). Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. Ophthalmology Retina. 9(9). 848–859. 2 indexed citations

Chakravarthy, Usha, Varun Chaudhary, Srinivas R. Sadda, et al.. (2025). Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. Ophthalmology Science. 5(5). 100798–100798. 1 indexed citations

Abreu, Francis, Caroline R. Baumal, Dolly S. Chang, et al.. (2024). Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefe s Archive for Clinical and Experimental Ophthalmology. 262(11). 3437–3451. 15 indexed citations

Tadayoni, Ramin, Liliana P Paris, Carl J. Danzig, et al.. (2024). Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion. Ophthalmology. 131(8). 950–960. 29 indexed citations

Maunz, Andreas, Usha Chakravarthy, Nancy M. Holekamp, et al.. (2024). Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema. Investigative Ophthalmology & Visual Science. 65(5). 26–26. 8 indexed citations

Hattenbach, Lars‐Olof, Francis Abreu, Karen Basu, et al.. (2023). BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion. SHILAP Revista de lepidopterología. 3(3). 100302–100302. 16 indexed citations

Kågedal, Matts, Mauricio Maia, Tong Lu, et al.. (2023). Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration. The Journal of Clinical Pharmacology. 63(11). 1210–1220. 4 indexed citations

Willis, Jeffrey R., et al.. (2023). Physical Activity in Functionally Monocular Persons in the United States, 2003–2006. Translational Vision Science & Technology. 12(2). 13–13.

10.

Guymer, Robyn H., Carlos Quezada-Ruiz, Jeffrey R. Willis, et al.. (2021). Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design. Investigative Ophthalmology & Visual Science. 62(8). 429–429.

11.

Wells, John A., Charles C. Wykoff, Jeffrey R. Willis, et al.. (2021). Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials. Investigative Ophthalmology & Visual Science. 62(8). 1037–1037. 2 indexed citations

12.

Willis, Jeffrey R., Ferhina S. Ali, Amitha Domalpally, et al.. (2021). Feasibility Study of a Multimodal, Cloud-Based, Diabetic Retinal Screening Program in a Workplace Environment. Translational Vision Science & Technology. 10(6). 20–20. 1 indexed citations

13.

Eter, Nicole, Rishi P. Singh, Francis Abreu, et al.. (2021). YOSEMITE and RHINE. SHILAP Revista de lepidopterología. 2(1). 100111–100111. 43 indexed citations

14.

Chakravarthy, Usha, Clare Bailey, Peter H. Scanlon, et al.. (2020). Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk Factors. Ophthalmology Retina. 4(7). 662–672. 43 indexed citations

15.

Arcadu, Filippo, Fethallah Benmansour, Andreas Maunz, et al.. (2019). Deep learning algorithm predicts diabetic retinopathy progression in individual patients. npj Digital Medicine. 2(1). 92–92. 188 indexed citations breakdown →

16.

Arcadu, Filippo, Fethallah Benmansour, Andreas Maunz, et al.. (2019). Deep learning algorithm for patient-level prediction of diabetic retinopathy (DR) response to vascular endothelial growth factor (VEGF) inhibition. Investigative Ophthalmology & Visual Science. 60(9). 2806–2806. 2 indexed citations

17.

Willis, Jeffrey R., et al.. (2018). Treatment patterns for diabetic macular edema (DME) in the United States: Analysis of the IRIS® Registry (Intelligent Research in Sight). Investigative Ophthalmology & Visual Science. 59(9). 2604–2604. 2 indexed citations

18.

Lansbury, Nina, Sylvie Albert, Syed Mansoor Ali, et al.. (2016). The UN Sustainable Development Goals for Water and Sanitation: How should Australia respond within and beyond its borders?. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 3 indexed citations

19.

Willis, Jeffrey R., Susan Vitale, Yuri Agrawal, & Pradeep Y. Ramulu. (2013). Visual Impairment, Uncorrected Refractive Error, and Objectively Measured Balance in the United States. JAMA Ophthalmology. 131(8). 1049–1049. 46 indexed citations

20.

Darmstadt, Gary L., Atanu Kumar Jana, Samir K. Saha, et al.. (2007). Determination of Extended-Interval Gentamicin Dosing for Neonatal Patients in Developing Countries. The Pediatric Infectious Disease Journal. 26(6). 501–507. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact